ARTICLE | Clinical News
Acute intermittent porphyria therapeutic regulatory update
October 7, 2002 7:00 AM UTC
The FDA granted Orphan Drug designation to HemeBiotech for an undisclosed compound that is in Phase I/II testing to treat acute intermittent porphyria, a hereditary disease related to porphyrin metabo...